Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-13

Study Completion Date

2022-05-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recombinant acellular pertussis vaccines containing genetically detoxified Pertussis Toxin (PTgen) have been used for booster immunisation in children, adolescents and adults including pregnant women in Thailand. Three vaccines have been licensed in Thailand, a monovalent (aPgen) and two vaccines combined with tetanus and reduced diphtheria dose vaccines (TdaPgen and Tdapgen). To address the need for improved vaccines in younger children, a new recombinant pediatric DTaP vaccine (DTaPgen) containing 5 µg genetically detoxified Pertussis Toxin (PTgen) and 10 µg Filamentous Hemagglutinin (FHA) was developed and found safe and immunogenic in a phase II trial in children aged 3 years onwards.

The purpose of this study is to assess the immunogenicity and safety of this new pediatric formulation DTaPgen given as the first booster dose in healthy toddlers aged 15 to 36 months compared to a commercially available vaccine in Thailand.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

NCT05091619

Whooping Cough Diphtheria Tetanus

ACTIVE_NOT_RECRUITING PHASE3

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

NCT05951725

Diphtheria, Tetanus and Acellular Pertussis

ACTIVE_NOT_RECRUITING PHASE3

5-year Follow-up After a Single Dose Acellular Pertussis Vaccination

NCT04529720

Pertussis

COMPLETED

Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .

NCT04099303

Diphtheria Tetanus Pertussis

COMPLETED PHASE1

Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants

NCT06344065

Healthy Volunteers

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II/III randomized, observer-blind, active-controlled study conducted in Thailand, children aged 15-36-month-old with a history of DTwP (n=240) or DTaP (n=50) priming were randomized 2:1 to receive a dose of recombinant DTaPgen or licensed DTaP-IPV. The aim of this study is to evaluate the safety and non-inferior immunogenicity of DTaPgen versus DTaP-IPV vaccine given as the first booster dose in toddlers.

Safety up to 1-year and vaccine antibody persistence will also be assessed for all children.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pertussis Whooping Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine

Participants who having completed the 3 doses DTwP or 3-dose DTaP vaccination (on interchange of DTwP and DTaP during primary immunization) will be randomized to receive Acellular pertussis (DTaP) vaccine (0.5 ml) given by intramuscularly as a single dose

Group Type EXPERIMENTAL

Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine

Intervention Type BIOLOGICAL

A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml will be given by intramuscularly at Day 0

Licensed DTaP

Participants who having completed the 3 doses DTwP or 3-dose DTaP vaccination (on interchange of DTwP and DTaP during primary immunization) will be randomized to receive Acellular pertussis (DTaP) vaccine (0.5 ml) given by intramuscularly as a single dose

Group Type ACTIVE_COMPARATOR

Licensed DTaP

Intervention Type BIOLOGICAL

A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml. will be given by intramuscular as at Day 0

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine

A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml will be given by intramuscularly at Day 0

Intervention Type BIOLOGICAL

Licensed DTaP

A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml. will be given by intramuscular as at Day 0

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 15 to 36 months of age at the time of vaccination.
2. Having completed the 3-dose DTwP or 3-dose DTaP vaccination (no interchange of DTwP and DTaP during primary immunization).
3. The parents or legal guardians of the participant are able to read and write.
4. The parents or legal guardians can provide written informed consent.
5. Healthy, as established by pertinent medical history and physical examination.

Exclusion Criteria

1. History of any significant medical illness such as, but not limited to, immune deficiency, renal, hepatic, cardiovascular, or endocrine disorder as determined by the investigator based on medical history and physical examination.
2. History of allergy or hypersensitivity to any vaccine (including its component).
3. History of any serious adverse event or neurological adverse event after vaccination.
4. Having received only 1 or 2 doses of DTwP or DTaP (incomplete primary immunization) after birth until the study enrollment.
5. Having received the 4th dose DTwP or DTaP vaccination.
6. Having experienced a physician diagnosed diphtheria or tetanus or pertussis illness within 1 year prior to recruitment.
7. Receipt of any vaccine within 28 days prior to enrollment (3 months for live-attenuated vaccines).
8. Planning to receive tetanus, diphtheria, pertussis or planning to participate in another clinical trial during the study period (approximately 1 year).
9. Receipt of blood or blood component or immunoglobulin within 3 months prior to recruitment.
10. History of receiving any immunosuppressive drug or systemic corticosteroid (more than 0.5 mg/kg of prednisolone or equivalent for more than 14 days) within 3 months prior to recruitment.
11. Any bleeding disorder.
12. Any abnormality of splenic or thymic function.
13. Any progressive or severe neurological disorder such as seizure disorder or Guillain- Barre syndrome;
14. History of any illness including cognitive impairment and psychiatric disease that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants due to participation in the study.
15. Fever as defined by body temperature more than 38 degree celsius at the time of enrollment (temporary exclusion criterion).

Minimum Eligible Age

15 Years

Maximum Eligible Age

36 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes